Say Hello to BrainGuide
Our platform BrainGuide™ empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.
UsAgainstAlzheimer's 2020 Annual Report
The UsAgainstAlzheimer's 2020 Annual Report features milestones from this past year as well as highlights from a decade of impact in the fight against Alzheimer's disease.
New Data Spotlights the Congressional Districts with the Highest Prevalence of Alzheimer’s among Blacks and Latinos
UsAgainstAlzheimer’s Center for Brain Health Equity released a new data brief highlighting the 41 congressional districts with the highest prevalence of Alzheimer’s disease and related dementias (ADRD) among Black Americans and Latinos in the traditional Medicare program. The brief details how government leaders can take action to help these hard-hit communities of color.
New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial
UsAgainstAlzheimer’s calls on Biogen, the FDA and insurers to come together to solve four key issues that are critical for patients: affordability, equity, the length and diversity of the Phase 4 confirmatory trial, and who is most likely to benefit from the drug.
UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s
UsAgainstAlzheimer’s issued the following statement from George Vradenburg, chairman and co-founder, on the Food and Drug Administration’s decision to approve Biogen’s aducanumab, the first disease-modifying therapy for early-stage Alzheimer’s.
Say Hello to BrainGuide
UsAgainstAlzheimer's 2020 Annual Report
New Data Spotlights the Congressional Districts with the Highest Prevalence of Alzheimer’s among Blacks and Latinos
New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial
UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s
UsAgainstAlzheimer's: Working to End Alzheimer's Disease
The Alzheimer’s pandemic is the health and social economic crisis of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.
UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s.
We bring all of “Us” together to:
- Improve brain health and promote earlier detection, diagnosis and intervention
- Champion health equity and access for communities of color and women who are disproportionately impacted by the disease
- Advocate for increased research spending that will speed treatments to market
- Drive changes that matter most to people living with the disease and caregivers
In the past decade, progress has been made, with more hope on the horizon now than ever before.
But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.